[The Breast Cancer Cohort Study in Chinese Women: the methodology of population-based cohort and baseline characteristics].
Heling Bao(Chinese Academy of Medical Sciences & Peking Union Medical College), L H Wang(Fuzhou Maternity and Child Health Care Hospital), Min Fan(University of Hong Kong), L Y Liu(Second Hospital of Shandong University), Weiwei Shi(Brigham and Women's Hospital), Shu Cong(National Center for Chronic and Noncommunicable Disease Control and Prevention), Muqing Cao(Taixing People's Hospital), Cuizhi Geng(Hebei Medical University), Xiaolei Guo(Yangzhou Polytechnic Institute), Zhigang Yu(University of Michigan), Shulin Yang(Tongji Hospital), Zhentao Fu(Shandong Center for Disease Control and Prevention), X N Duan(Peking University), Jialing Tang(Shandong Center for Disease Control and Prevention), Jixin Sun(Hebei Provincial Center for Disease Control and Prevention), Liwen Fang(Chinese Center For Disease Control and Prevention)
Cited by 6
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Salt Substitution on Cardiovascular Events and Death
|New England Journal of Medicine|2021|726
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|490
Rational Design of Better Hydrogen Evolution Electrocatalysts for Water Splitting: A Review
|Advanced Science|2022|429